[Cytokines as biomarkers of the patients state severity and prognostication in burns: new therapeutic possibilities of existing approaches in treatment. Part 2].
O M
OM
Kovalenko
D B
DB
Mal'tsev
V Ie
VIe
Kazmirchuk
H P
HP
Kozynets
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D057134:Antibodies, Neutralizing / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002056:Burns / Q000150:complications / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000276:immunology; D006801:Humans; D011379:Prognosis; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors* / Q000276:immunology; D012720:Severity of Illness Index; D016038:Skin Transplantation; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications / Q000276:immunology / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D015415:Biomarkers; D016207:Cytokines; D018121:Receptors, Cytokine